{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.3","upperLimit":"89.7","value":"81.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants from the BAT arm at the end of Cycle 6 crossed over to ruxolitinib treatment.","id":"OG000","title":"Ruxolitinib Cross-Over Period"}],"paramType":"NUMBER","populationDescription":"Cross-over Analysis Set","reportingStatus":"POSTED","timeFrame":"from Crossover Cycle 1 Day 1 to any time point up to and including Crossover Cycle 7 Day 1 (each cycle was comprised of 4 weeks)","title":"BOR During Cross-over Treatment With Ruxolitinib","type":"SECONDARY","unitOfMeasure":"percentage of participants"}